Status:
COMPLETED
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Amgen
Conditions:
Solid Tumors
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received ch...
Detailed Description
Platelets are cells that help make the blood clot. A decrease in platelets can cause bleeding, which may prevent or delay a patient from receiving chemotherapy. Researchers want to find out if AMG 531...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of solid tumors who are at high risk for chemotherapy-induced severe thrombocytopenia related to the following regimens: (a) Carboplatin (AUC=11); (b) AI regimen (adriamycin 75-90mg/m2, Ifosfamide 10gm/m2); (c) High dose Ifosfamide (14gm/m2)
- Age \>/= 18 years.
- Adequate hematologic (Absolute neutrophil count (ANC) \>/= 1500/mm\^3, platelet count \>/= 100 x 10\^9/L and Hgb \>/= 8 gm/dL), renal (serum creatinine \</= 2.0 mg/dL), and hepatic functions (total bilirubin \</= 2 times, aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT) \</= 3 times the upper limit of the respective normal range).
- Karnofsky Performance Status \>/= 80
- Signed informed consent form
- Patients with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) must have a negative pregnancy test and use adequate birth control. \[i.e. oral contraceptives, spermicide with either a condom, diaphragm or cervical cap, use of an intrauterine device (IUD), or abstinence\].
Exclusion
- Patients with rapidly progressive disease (such as patients with rapidly accumulating ascites or pleural effusion).
- Patients with hematologic malignancies.
- Pregnant or lactating women.
- History of central nervous system (CNS) metastasis.
- Patients with significant cardiac disease (New York Hearth Association (NYHA) Class III or IV), dysrrhythmia, or recent history of MI or ischemia, transient ischemic attack or cerebrovascular accident (CVA), within the previous 6 months of study entry.
- Patients with a history of thromboembolic events (history of deep venous thrombosis (DVT) or pulmonary embolus).
- Prior chemotherapy, immunotherapy, or experimental drug (not FDA-approved drug) within 3 weeks. Patients will be eligible if day 1 of chemotherapy was initiated 3 weeks prior to study entry if the patient has recovery of blood counts and from acute toxicity of chemotherapy as described in inclusion criteria # 3.
- Use of nitrosourea (carmustine (BCNU), lomustine (CCNU) or mitomycin - C within 6 weeks of study entry.
- Prior surgery or Radiation Therapy (RT) within 2 weeks of study entry.
- Patients with history of prior whole pelvic radiation will be excluded unless there is no prior history of severe thrombocytopenia (i.e. platelet nadir \<10,000/mm\^3)
- Patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (\>/= 2 weeks).
- History of any platelet disorders including Idiopathic thrombocytopenic purpura (ITP), Thrombotic thrombocytopenic purpura (TTP) or bleeding disorders.
- History of \> 4 prior chemotherapy regimens (all platinum regimens will be counted as one regimen).
- Patients with significant bowel dysfunction secondary to tumor (significant abdominal pain with severe constipation/diarrhea (\>/= Grade 3), significant difficulty maintaining oral nutrition).
- Patients with pre-existing neuropathy \> Grade 2.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00147225
Start Date
August 1 2005
End Date
March 1 2013
Last Update
May 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030